CTOs on the Move

ATAI Life Sciences

www.atai.life

 
Bridging the gap between what the #mentalhealth system can provide and what people need. Interested in #psychedelics, #drugdevelopment, and #AI. CEO @FloBrand.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.atai.life
  • 677, Huntington Avenue
    Boston, MA USA 02115
  • Phone: +49.89.2153903

Executives

Name Title Contact Details

Similar Companies

Scientific Specialties

Leading innovator in Life Science Laboratory Consumables: Pipette Tips; PCR; Screw Cap, Centrifuge, and Cryogenic Tubes; HTS; and Tubes Racks.

FluroTech

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech`s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples derived from cannabis plants. Using the technology that was developed at the University of Calgary in conjunction with the University of Alberta, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

Elemental Enzymes

It is widely accepted that enzyme delivery technologies are the wave of the future, they require little to no additional energy, they are widely available, and are extremely efficient. However, their use in many of today’s industrial processes is lim...

Vaxxas

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology. In addition to HD-MAP HexaPro clinical studies of a COVID-19 vaccine patch, Vaxxas is performing demonstration work in preparation for clinical evaluation under contract with the United States Biomedical Advanced Research and Development Authority (BARDA) on pandemic vaccination solutions. Vaxxas core technology was initially developed at the University of Queensland. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Partners, Brandon BioCatalyst, and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.

Vivacelle Bio

Welcome to Vivacelle Bio Inc.